Literature DB >> 11113579

In vitro and in vivo characterization of hNT neuron neurotransmitter phenotypes.

S Saporta1, A E Willing, L O Colina, T Zigova, M Milliken, M M Daadi, P R Sanberg.   

Abstract

The hNT neuron exhibits many characteristics of neuroepithelial precursor cells, making them an excellent model to study neuronal plasticity in vitro and in vivo. These cells express a number of neurotransmitters in vitro, including dopamine, gamma-aminobutyric acid and acetylcholine. However, there have been few reports of the neurotransmitters that hNT neurons express in vivo. The present study examined whether hNT neurons express the same neurotransmitters in vivo as they do in vitro. First, the expression of tyrosine hydroxylase (TH), glutamic acid decarboxylase (GAD), choline acetyltransferase (ChAT) and the human specific nuclear marker NuMA by hNT neurons was confirmed. Nineteen normal animals were then transplanted with 80,000 hNT neurons aimed at the striatum, hippocampus or cerebral cortex. Five additional animals received injections of medium. All animals received daily intraperitoneal injections of cyclosporine (10 mg/kg) and survived 30 days. Sections through the transplants were examined for NuMA-positive hNT neurons, and for the presence of the three neurotransmitter markers: TH, GAD and ChAT. The hNT neurons were found in the striatum and cortex. Of the hNT neurons found within the rat striatum, 33% were ChAT-positive. In the cortex, only 4% of the neurons expressed ChAT. No GAD-positive hNT neurons were detected at either site. No NuMA-positive neurons were found in the hippocampus. The implanted hNT neurons did not induce activation of astrocytes as determined by immunocytochemistry for glial fibrillary acidic protein (GFAP). Moreover, no hNT neuron was found to express GFAP in vivo. Together, these data suggest that the hNT neurons engraft in the new host tissue, maintain their neuronal identity and may be guided in differentiation according to local environmental cues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113579     DOI: 10.1016/s0361-9230(00)00329-4

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  7 in total

Review 1.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  The role of connexins in the differentiation of NT2 cells in Sertoli-NT2 cell tissue constructs grown in the rotating wall bioreactor.

Authors:  R Shamekh; D F Cameron; A E Willing; S Saporta
Journal:  Exp Brain Res       Date:  2005-11-19       Impact factor: 1.972

3.  Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo.

Authors:  Ming Yang; Angela E Donaldson; Cheryl E Marshall; James Shen; Lorraine Iacovitti
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

4.  Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation.

Authors:  Peter T Nelson; Douglas Kondziolka; Lawrence Wechsler; Steven Goldstein; James Gebel; Sharon DeCesare; Elaine M Elder; Paul J Zhang; Alan Jacobs; Michael McGrogan; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Stem cell therapy for Parkinson's disease.

Authors:  Lars M Björklund
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

6.  Review of the history and current status of cell-transplant approaches for the management of neuropathic pain.

Authors:  Mary J Eaton; Yerko Berrocal; Stacey Q Wolfe; Eva Widerström-Noga
Journal:  Pain Res Treat       Date:  2012-06-14

7.  Potential for Cell-Transplant Therapy with Human Neuronal Precursors to Treat Neuropathic Pain in Models of PNS and CNS Injury: Comparison of hNT2.17 and hNT2.19 Cell Lines.

Authors:  Mary J Eaton; Yerko Berrocal; Stacey Q Wolfe
Journal:  Pain Res Treat       Date:  2012-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.